Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Opthea ( (AU:OPT) ) just unveiled an update.
Opthea Limited has notified the Australian Securities Exchange that a total of 4,451,086 options and related conditional rights have ceased, comprising 4,000,000 options that expired unexercised on 19 October 2025 and a further 451,086 conditional rights that lapsed on 11 November 2025 after conditions were not met. The cessation of these securities results in a modest simplification of Opthea’s capital structure and signals that a portion of previously potential equity dilution will no longer occur, which may slightly alter dilution expectations for existing shareholders but does not, on its face, indicate any change to the company’s underlying operations or development programs.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.56 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is an Australian-listed biotechnology company focused on developing ophthalmic therapies, with its shares traded on the ASX under the code OPT. The company operates in the life sciences sector, where capital structure changes, including options and other convertible securities, are a routine part of financing and incentivising development-stage activities.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
Learn more about OPT stock on TipRanks’ Stock Analysis page.